Advancing More Personalized Therapies for Rare & Common Kidney Diseases
March 17-19, 2025 | Boston, MA
Welcome to the Definitive Industry Focused Forum for Innovating Renal Drug Development
Advance More Personalized Therapies for Rare & Common Kidney Diseases
The transformative era of kidney drug development is here, with 2024 bringing landmark advancements, including Novartis’ Borealis Biosciences and approvals in IgAN, Travere Therapeutics, and industry-defining acquisitions by Biogen and Vertex. Breakthrough therapies like SGLT2 inhibitors, GLP-1s, and MRAs continue to reshape the CKD treatment paradigm, while the FDA’s accelerated pathways fuel unprecedented innovation. We are witnessing a renaissance in chronic kidney disease research and development and treatment.
The 7th CKD Drug Development Summit returns in 2025 as the definitive forum for connecting industry leaders, KOLs, researchers, and regulators. Addressing the most pressing challenges across renal research and development, this event serves as the unrivaled platform to share breakthroughs, inspire collaboration, and advance strategies for improving clinical outcomes in renal care all to bring better drugs to patients faster.
2025 Event Guide
What's On?
2 Track Conference
The flagship summit returns for its 7th iteration with an end-to-end program full of unrivaled scientific content across three tracks, perfect for all your teams:
- Track 1: Discovery, Preclinical & Translational
- Track 2: Clinical Innovation, Regulatory & Outcomes Track
Glomerular Focus Day
This summit showcases groundbreaking research into novel targets, pipeline breakthroughs, and real-world patient studies with exclusive insights from the FDA, Apellis Pharmaceuticals, NephCure Kidney International, Travere Therapeutics, and more.
Deep-Dive Workshop Day
Deep dive into three discussion-based workshops from translating omics data and RWE into meaningful insights for development, advancing pediatric nephrology, and mastering hierarchical composite endpoints to supercharge the next generation of therapeutics with Alexion, Purespring, and Boehringer Ingelheim.
Scientific Poster Session
Showcase your groundbreaking research, understand what your peers are working on, and discover the latest innovations in CKD.
10+ Hours of Networking
Network and forge valuable connections and reconnect with industry leaders through drinks receptions, speed networking sessions, lunch briefings, and more. You could have Joined over 200+ CKD experts from various sectors within the biopharma landscape.
40+ Expert Speakers
Hear cutting-edge pipeline updates, promising pediatric trial data, and regulatory insights on the evolving landscape of acceptable surrogate endpoints.
2025's Speaker Faculty Includes:
Aliza Thompson
Deputy Director of the Division of Cardiology & Nephrology
US Food & Drug Administration
Carol Moreno Quinn
Head of Immunology, Infectious Diseases, Cardiovascular, Renal & Metabolism, Global Medical Affairs
Roche
2025 Partners:
Hear What Our Past Attendees Say
“One of the few events in the calendar which brings together such a large group of world leading experts in kidney drug development from multiple fields, fully focused and dedicated on how to improve the care for patients living with kidney disease.”
Dominik Steubl, Senior Clinical Program Leader, Boehringer Ingelheim
“The power of this Summit comes from both the diversity of topics and the diversity of subject matter experts across Industry, Academia, Health Care Authorities, and Patient Groups.”
Manish Maski, Head, Global Rare Nephrology Medical Affairs, Sanofi
“A one-of-a-kind unique blend of leaders in the Nephrology community, industry and science discussing exciting advances in biology and treatment of kidney diseases.”
Dermot Reilly, Director, Genetics & Translational Biology, Johnson & Johnson
Attending Companies:
Other Events in the Series
